Eli Lilly to Acquire Three Vaccine Developers for Up to $3.8 Billion

Eli Lilly & Co. aims to extend its success in obesity treatment to become a leader in infectious diseases. The company has signed agreements to acquire three clinical-stage vaccine developers for a total of up to $3.8 billion. The deals will provide access to new technologies and experimental vaccines from Curevo, LimmaTech Biologics, and Vaccine Company. These vaccines are being developed against shingles, common bacterial pathogens, and the Epstein-Barr virus. Dan Skovronsky, Lilly's chief scientific and product officer, stated that these acquisitions represent a deliberate strategy to prevent disease at its source rather than treating its consequences. Bloomberg Intelligence analysts view this move as an effort by Lilly to diversify its portfolio and increase growth potential in the infectious disease space. This is not investment advice.

📊 LLY — Piyasa Yorumu

▲ up · 65%

The news is likely to be received positively as a strategic acquisition that strengthens Eli Lilly's vaccine portfolio. Although the RSI above 75 indicates overbought conditions, the MACD above the signal line and the price trading above both the 20-day and 50-day moving averages support a strong uptrend. The 6.7% increase in the last 24 hours suggests the market has reacted favorably to the news. The upward trend is expected to continue in the short term, though there is a risk of some profit-taking due to overbought conditions.

RSI 14

75.8

MACD

16.37

24h Δ

6.69%

Canlı Grafikler